書籍詳細

第1編 病態と栄養

P.7 掲載の参考文献

• 1) Daar AS, Singer PA, Persad DL, Pramming SK, Matthews DR, Beaglehole R, Bernstein A, Borysiewicz LK, Colagiuri S, Ganguly N, Glass RI, Finegood DT, Koplan1 J, Nabel1 EG, Sarna G, Sarrafzadegan N, Smith 1 R, Yachl D, Bellchronic J:Grand challenges in chronic noncommunicablediseases. Nature 450;494-496;2007

• 2) 田中清, 武田英二, 門脇孝, 恩地森一, 立川倶子, 清野裕: 生活習慣病の治療・予防における栄養療法の意義と医療経済評価. 日本病態栄養学会誌 9; 3-9; 2006
  Medical*Online

• 3) 患者調査の概要 平成17年版: 厚生労働省

• 4) 高齢社会白書 平成16, 19年版: 政府広報オンライン

• 5) http://nutrigenomics.ucdavis.edu/
  pubmed

P.20 掲載の参考文献

• 1) Holmugren A.:Thioredoxin. Annu Rev Biochem 1985;54:237-271.
  pubmed

• 2) Tagaya Y., Maeda Y., Mitsui A., et al.:ATL-derived factor (ADF), an IL-2 receptor/Tac inducer homologous to thioredoxin ; possible involvement of dithiol-reduction in the IL-2 receptor induction. EMBO J 1989;8;757-764.

• 3) Das K. C., Das C. K.:Thioredoxin, a singlet oxygen quencher and hydroxyl radical scavenger:redox independent functions. Biochem Biophys Res Commun 2000;277;443-447.
  pubmed

• 4) Tamura T, Stadtman TC.:A new selenoprotein from human lung adenocarcinoma cells:purification, properties, and thioredoxin reductase activity. Proc Natl Acad Sci U S A. 1996;93;1006-1011.
  pubmed

• 5) Matsui M., Oshima M., Oshima H., et al.:Early embryonic lethality caused by targeted disruption of the mouse thioredoxin gene. Dev Biol 1996;178;179-185.
  pubmed

• 6) Mitsui A., Hamuro J., Nakamura H. et al.:Overexpression of human thioredoxin in transgenic mice controls oxidative stress and life span. Antioxid Redox Signal 2002;4;693-696.
  pubmed

• 7) Nakamura H., Herzenberg L. A., Bai J. et al.:Circulating thioredoxin suppresses lipopolysaccharide-induced neutrophil chemotaxis. Proc Natl Acad Sci U S A. 2001;98;15143-15148.
  pubmed

• 8) Hoshino T., Nakamura H., Okamoto M. et al.:Redox-active protein thioredoxin prevents proinflammatory cytokine- or bleomycin-induced lung injury. Am J Respir Crit Care Med 2003;168;1075-1083.
  pubmed

• 9) Sato A. Hara T. Nakamura H. et al.:Thioredoxin-1 suppresses systemic inflammatory responses against cigarette smoking. Antioxid Redox Signal. 2006;8;1891-1896.
  pubmed

• 10) Son A., Nakamura H., Kondo N. et al.:Redox regulation of mast cell histamine release in thioredoxin-1 (TRX) transgenic mice. Cell Res 2006;16;230-239.
  pubmed

• 11) Tamaki H., Nakamura H., Nishio A. et al.:Human thioredoxin-1 ameliorates experimental murine colitis in association with suppressed macrophage inhibitory factor production. Gastroenterology 2006;131;1110-1121.
  pubmed

• 12) Kim Y. C., Yamaguchi Y., Kondo N. et al.:Thioredoxin-dependent redox regulation of the antioxidant responsive element (ARE) in electrophile response. Oncogene. 2003;22;1860-1865.
  pubmed

• 13) Bai J, Nakamura H, Kwon Y. W. et al.:Critical roles of thioredoxin in nerve growth factor-mediated signal transduction and neurite outgrowth in PC12 cells. J Neurosci 2003;23;:503-509.
  pubmed

• 14) Dekigai H. Nakamura H. Bai J. et al.:Geranylgeranylacetone promotes induction and secretion of thioredoxin in gastric mucosal cells and peripheral blood lymphocytes. Free Radic Res. 2001;35:23-30.
  pubmed

• 15) Hirota K. Nakamura H. Arai T. et al.:Geranylgeranylacetone enhances expression of thioredoxin and suppresses ethanol-induced cytotoxicity in cultured hepatocytes. Biochem Biophys Res Commun. 2000;275;825-830.
  pubmed

• 16) Yamamoto M. Sato N. Tajima H et al.:Induction of human thioredoxin in cultured human retinal pigment epithelial cells through cyclic AMP-dependent pathway;involvement in the cytoprotective activity of prostaglandin E1. Exp Eye Res 1997;65;645-652.
  pubmed

• 17) Masutani H. Yamaguchi Y. Otsuki R. et al.:Thioredoxin and Thioredoxin inducers against oxidative stress. J Clin Biochem Nutr. 2005;37;45-53

• 18) Tanito M, Masutani H, Kim YC. et al.:Sulforaphane induces thioredoxin through the antioxidant-responsive element and attenuates retinal light damage in mice. Invest Ophthalmol Vis Sci. 2005;46;979-987.
  pubmed

• 19) Tan A. Nakamura H. Kondo N. et al.:Thioredoxin-1 attenuates indomethacin-induced gastric mucosal injury in mice. Free Radic Res;2007;41;861-869.
  pubmed

• 20) Maeta K. Izawa S. Okazaki S. et al.:Activity of the Yap 1 transcription factor in Saccharomyces cerevisiae is modulated by methylglyoxal, a metabolite derived from glycolysis. Mol Cell Biol 2004;24;8753-8764.

• 21) Takatsume Y. Maeta K. Izawa S. et al.:Enrichment of yeast thioredoxin by green tea extract through activation of Yap1 transcription factor in Saccharomyces cerevisiae. J Agric Food Chem 2005;53;332-337.
  pubmed

• 22) Maeta K. Nomura W. Takatsume Y. et al.:Green tea polyphenols function as prooxidants to activate oxidative stress-responsive transcription factors in yeasts. Appl Environ Microbiol 2007;73;572-580.
  pubmed

• 23) Takatsume Y. Izawa S. Inoue, Y.:Methylglyoxal as a signal initiator for activation of the stress-activated protein kinase cascade in the fission yeast Schizosaccharomyces pombe. J Biol. Chem 2006;281;9086-9092.
  pubmed

• 24) Maeta K. Izawa S. Inoue, Y.:Methylglyoxal, a metabolite derived from glycolysis, functions as a signal initiator of the high osmolarity glycerol-mitogen-activated protein kinase cascade and calcineurin/Crz1-mediated pathwa iyn Saccharomyces cerevisiae. J Biol Chem 2005;280;253-260.

P.30 掲載の参考文献

• 1) Brown MS, Goldstein JL:A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc Natl Acad Sci U S A 1999 Sep 28;96(20);11041-8

• 2) Shimano H et al.:Sterol Regulatory Element-binding protein-1 as a key transcription factor for nutritional induction of lipogenic enzyme genes.

• 3) Shimano H.:Sterol Regulatory Element-binding Protein (SREBP) Family as Global Regulators of Lipid Synthetic Genes in Energy Metabolism. Vitamins and Hormones 2002;65;167-94

• 4) Hasty AH, Shimano H, Osuga J, Namatame I, Takahashi A, Yahagi N, Perrey S, Iizuka Y, Tamura Y, Amemiya-Kudo M, Yoshikawa T, Okazaki H, Ohashi K, Harada K, Matsuzaka T, Sone H, Gotoda T, Nagai R, Ishibashi S, Yamada N.:Severe hypercholesterolemia, hypertriglyceridemia, and atherosclerosis in mice lacking both leptin and the low density lipoprotein receptor. J Biol Chem. 2001 Oct 5;276(40);37402-8.

• 5) Ide T, Shimano H, and Yahagi N et al.:SREBPs suppress IRS-2-mediated insulin signalling in the liver. Nat Cell Biol 6(4);351-357;2004.

• 6) Shimano H.:SREBP-1 c and TFE 3, energy transcription factors that regulate hepatic insulin signaling. J Mol Med. 2007 Feb 6 [Epub ahead of print]

• 7) Yahagi N, Shimano H, Hasty AH, Amemiya-Kudo M, Okazaki H, Tamura Y, Iizuka Y, Shionoiri F, Ohashi K, Osuga J, Harada K, Gotoda T, Nagai R, Ishibashi S, Yamada N.:A crucial role of sterol regulatory element-binding protein-1 in the regulation of lipogenic gene expression by polyunsaturated fatty acids. J Biol Chem. 1999 Dec 10;274(50);35840-4.

• 8) Sekiya M, Yahagi N, Matsuzaka T, Najima Y, Nakakuki M, Nagai R, Ishibashi S, Osuga J, Yamada N, Shimano H.:Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology. 2003 Dec;38(6);1529-39

• 9) Nakagawa Y, Shimano H, Yoshikawa T, Ide T, Tamura M, Furusawa M, Yamamoto T, Inoue N, Matsuzaka T, Takahashi A, Hasty AH, Suzuki H, Sone H, Toyoshima H, Yahagi N, and Yamada N:TFE 3 transcriptionally activates hepatic IRS-2, participates in insulin-signaling and, ameliorates diabetes. Nature Med Nat Med. 2006 Jan;12(1);107-113

• 10) Takahashi A, Motomura K, Kato T, Yoshikawa T, Nakagawa Y, Yahagi N, Sone H, Suzuki H, Toyoshima H, Yamada N, Shimano H.:Transgenic mice overexpressing nuclear SREBP-1c in pancreatic beta-cells. Diabetes. 2005 Feb;54 (2);492-9

• 11) Matsuzaka T, Shimano H, Yahagi N, Kato T, Atsumi A, Yamamoto T, Inoue N, Ishikawa M, Okada S, Ishigaki N, Iwasaki H, Iwasaki Y, Karasawa T, Kumadaki S, Matsui T, Sekiya M, :Ohashi K, Hasty AH, Nakagawa Y, Takahashi A, Suzuki H, Yatoh S, Sone H, Toyoshima H, Osuga J & Yamada N Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance. Nat Med. 2007 Nov;13(10);1193-1202. Epub 2007 Sep 30.

• 12) Kato T, Shimano H, Yamamoto T, Yokoo T, Endo Y, Ishikawa M, Matsuzaka T, Nakagawa UY, Kumadaki S, Yahagi N, Takahashi A, Sone H, Suzuki H, Toyoshima H, Hasty AH, Takahashi S, Gomi H, Izumi T, Yamada N.:Granuphilin is activated by SREBP-1c and involved in impaired insulin secretion in diabetic mice. Cell Metab. 2006 Aug;4(2);143-54.

• 13) Inoue N, Shimano H, Nakakuki M, Matsuzaka T, Nakagawa Y, Yamamoto T, Sato R, Takahashi A, Sone H, Yahagi N, Suzuki H, Toyoshima H, Yamada N.:Lipid Synthetic Transcription Factor SREBP-1a Activates p21 WAF1/CIP1, Universal Cyclin-Dependent Kinase Inhibitor. Mol Cell Biol. 2005, Oct 25(20);8938-47.
  pubmed

• 14) Shimano H.:SREBP-1 c and TFE 3, energy transcription factors that regulate hepatic insulin signaling. J Mol Med. 2007 May;85(5);437-444.

• 15) Shimano H, Amemiya-Kudo M, Takahashi A, Kato T, Ishikawa M, Yamada N. Sterol regulatory element-binding protein-1c and pancreatic beta-cell dysfunction. Diabetes Obes Metab. 2007 Nov;9 Suppl 2;133-9.

P.42 掲載の参考文献

• 1) Miki T., Nagashima K., Seino S.:The structure and function of the ATP-sensitive K+ channel in insulin-secreting pancreatic beta-cells. J Mol Endocrinol 1999;22;113-123.
  pubmed

• 2) Inagaki N., Gonoi T., Clement J. P. 4th, et al.:Reconstitution of IKATP:An inward rectifier subunit plus the sulfonylurea receptor. Science 1995;;270;1166-1170.
  pubmed

• 3) Inagaki N., Gonoi T., Seino S.:Subunit stoichiometry of the pancreatic beta-cell ATP-sensitive K+ channel. FEBS Lett 1997;409;232-236.
  pubmed

• 4) McQuarrie I.:Ideopathic spontaneously occurring hypoglycemia in infants:clinical significance of problem and treatment. Am J Dis Child 1954;87;399-428.

• 5) Shyng S. L., Ferrigni T., Shepard J. B., et al.:Functional analyses of novel mutations in the sulfonylurea receptor 1 associated with persistent hyperinsulinemic hypoglycemia of infancy. Diabetes 1998;47;1145-1151.
  pubmed

• 6) Otonkoski T., Ammala C., Huopio H., et al.:A point mutation inactivating the sulfonylurea receptor causes the severe form of persistent hyperinsulinemic hypoglycemia of infancy in Finland. Diabetes 1999;48;408-415.
  pubmed

• 7) Sharma N., Crane A., Gonzalez G., et al:Familial hyperinsulinism and pancreatic β-cell ATP-sensitive potassium channels. Kidney Int 2000;57;803-808.

• 8) Gloyn A. L., Pearson E. R., Antcliff J. F., et al.:Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir 6.2 and permanent neonatal diabetes. N Engl J Med 2004;350;1838-1849.

• 9) Yorifuji T., Nagashima K., Kurokawa K., et al.:The C42R Mutation in the Kir6.2 (KCNJ11) Gene as a Cause of Transient Neonatal Diabetes, Childhood Diabetes, or Later-Onset, Apparently Type 2 Diabetes Mellitus. J Clin Endocrinol Metab 2005;90;3174-3178.
  pubmed

• 10) Vaxillaire M., Populaire C., Busiah K., et al.:Kir6.2 mutations are a common cause of permanent neonatal diabetes in a large cohort of French patients. Diabetes 2004;53;2719-2722.

• 11) Gloyn A. L., Cummings E. A., Edghill E. L., et al.:Permanent neonatal diabetes due to paternal germline mosaicism for an activating mutation of the KCNJ11 Gene encoding the Kir6.2 subunit of the beta-cell potassium adenosine triphosphate channel. J Clin Endocrinol Metab 2004;89;3932-3935.

• 12) Edghill E. L., Gloyn A. L., Gillespie K. M. et al.:Activating mutations in the KCNJ11 gene encoding the ATP-sensitive K+ channel subunit Kir6.2 are rare in clinically defined type 1 diabetes diagnosed before 2 years. Diabetes 2004;53;2998-3001.
  pubmed

• 13) Sagen J. V., Raeder H., Hathout E., et al.:Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2:patient characteristics and initial response to sulfonylurea therapy. Diabetes 2004;53;2713-2718.
  pubmed

• 14) Pearson E. R., Flechtner I., Njolstad P. R. et al.:Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006;355;467-477.
  pubmed

• 15) Proks P., Arnold A. L., Bruining J., et al.:A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC 8) causes neonatal diabetes. Hum Mol Genet 2006;15;1793-1800.

• 16) Proks P., Shimomura K., Craig T. J., et al.:Mechanism of action of a sulphonylurea receptor SUR1 mutation (F132L) that causes DEND syndrome. Hum Mol Genet 2007;16;2011-2019.
  pubmed

• 17) Ellard S., Flanagan S. E., Girard C. A., et al.:Permanent neonatal diabetes caused by dominant, recessive, or compound heterozygous SUR1 mutations with opposite functional effects. Am J Hum Genet 2007;81;375-382.
  pubmed

• 18) MacDonald M. J., Fahien L. A., Brown L. J., et al.:Perspective:emerging evidence for signaling roles of mitochondrial anaplerotic products in insulin secretion. Am J Physiol Endocrinol Metab 2005;288;E1-15.
  pubmed

• 19) Corkey B. E., Glennon M. C., Chen K. S., et al.:A role for malonyl-CoA in glucose-stimulated insulin secretion from clonal pancreatic betacells. J Biol Chem 1989;264;21608-21612.
  pubmed

• 20) Prentki M., Joly E., El-Assaad W. et al.:Malonyl-CoA signaling, lipid partitioning, and glucolipotoxicity:role in beta-cell adaptation and failure in the etiology of diabetes. Diabetes 2002;51 Suppl 3;S405-413.

• 21) Itoh Y., Kawamata Y., Harada M., et al.:Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 2003;422:173-176.
  pubmed

• 22) Briscoe C. P., Tadayyon M., Andrews J. L., et al.: The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem 2003;278;11303-11311.
  pubmed

• 23) Hirasawa A., Tsumaya K., Awaji T., et al.: Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med 2005;11;90-94.
  pubmed

• 24) Nauck M. A., Bartels E., Orskov C., et al.:Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptidend glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993;76;912-917.
  pubmed

• 25) Vilsboll T., Krarup T., Sonne J., et al.:Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 2003;88;2706-2713.
  pubmed

• 26) Nauck M. A., Heimesaat M. M., Orskov C., et al.:Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993;91;301-307.

• 27) Fineman M. S., Bicsak T. A., Shen L. Z., et al.:Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003;26;2370-2377.
  pubmed

• 28) DeFronzo R. A., Ratner R. E., Han J., et al.:Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28;1092-1100.
  pubmed

• 29) Buse J. B., Henry R. R., Han J., et al.:Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27;2628-2635.
  pubmed

• 30) Kendall D. M., Riddle M. C., Rosenstock J., et al.:Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28;1083-1091.

• 31) Madsbad S., Schmitz O., Ranstam J., et al.:Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211):a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004;27;1335-1342.

• 32) Drucker D. J., Nauck M. A.:The incretin system:glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368;1696-1705.
  pubmed

• 33) Amori R. E., Lau J., Pittas AG.:Efficacy and safety of incretin therapy in type 2 diabetes:systematic review and meta-analysis. JAMA 2007;298;194-206.
  pubmed

P.54 掲載の参考文献

• 1) Lee N. K., et al.:Endocrine regulation of energy metabolism by the skeleton. Cell, 2007;130 (3);(456-69).

• 2) Zaidi M.:Skeletal remodeling in health and disease. Nature Medicine, 2007;13;(791-801).

• 3) Teitelbaum S. L., Ross F. P.:Genetic regulation of osteoclast development and function. Nature, 2003;4;(638-649).

• 4) Mangelsdorf D. J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., Blumberg B., Kastner P., Mark M., Chambon P., et al. . he nuclear receptor superfamily:the second decade. Cell, 1995;83;(835-839).

• 5) McKenna N. J., and B.W.O' Malley.:Combinatorial control of gene expressionby nuclear receptors and coregulators. Cell, 2002;108;(465-74).

• 6) Shi Y.:Histone lysine demethylases:emerging roles in development, physiology and disease. Nat Rev Genet, 2007;8(11);(829-33).

• 7) Rosenfeld M. G., Lunyak V. V., Glass C. K.:Sensors and signals:a coactivator/corepressor/epigenetic code for integrating signal-de-pendent programs of transcriptional response. Genes Dev, 2006;1;20(11);(1405-28).

• 8) Holick M. F.:Resurrection of vitamin D deficiency and rickets. J Clin Invest, 2006;116 (8);(2062-72).

• 9) Haussler M. R., Whitfield G. K., Haussler C. A., Hsieh J. C., Thompson P. D., Selznick S. H., Dominguez C. E., Jurutka P.W.:The nuclear vitaminD receptor:biological and molecular regulatory properties revealed. J Bone Miner Res, 1998;13;(325-349).

• 10) Yoshizawa T., Handa Y., Uematsu Y., Takeda S., Sekine K., Yoshihara Y., Kawakami T., Arioka K., Sato H., Uchiyama Y., Masushige S., Fukamizu A., Matsumoto T., Kato S.:Mice lacking the vitamin D receptor exhibit impaired bone formation. Unterine hypoplasia and growth retardation after weaning. Nature Genetics, 1997;16;(391-396).

• 11) Yagishita N., Yoshizawa T., Yamamoto Y., Sekine K., Uematsu Y., Murayama H., Nagai Y., Krezel W., Chambon P., Matsumoto T., Kato S.:Aberrant growth plate development in VDR/RXR gamma double null mutant mice. Endocrinology, 2001;142;(5332-5341).

• 12) Li M., Indra A. K., Warot X., Brocard J., Messaddeq N., Kato S., Metzger D., Chambon P.:Skin abnormalities generated by temporally controlled RXRalpha mutations in mouse epidermis. Nature, 2000;407;(633-636).

• 13) Masuyama, R., Nakaya Y, Tanaka, S., Tsurukami, H., Nakamura, T., Watanabe, S,. Yoshizawa, T., Kato, S., Suzuki, K.:Dietary phosphorus restriction reverses the impaired bone mineralization in vitamin D receptor knockout mice. Endocrine, 2001;142;(494-497).

• 14) Vanderschueren D., Vandenput L., Boonen S., Lindberg M L., Bouillo R., Ohlsson C.:Androgens and Bone. Endocrine Reviews, 2004;25 (3);(389-425).

• 15) Kawano H., Sato T., Yamada T., Matsumoto T., Sekine K., Watanabe T., Nakamura T., Fukuda T., Yoshimura K., Yoshizawa T., Aihara K., Yamamoto Y., Nakamichi Y., Metzger D., Chambon P., Nakamura K., Kawaguchi H., Kato S.:Suppressive function of androgen receptor in bone resorption. Proc Natl Acad Sci USA 100, 2003;(9416-942114).

• 16) Syed F., Khosla S.:Mechanisms of sex steroid effects on bone. BBRC, 2005;328;(688-696).

• 17) Fitzpatrick L. A.:Estrogen therapy for postmenopausal osteoporosis. Arq Bras Endocrinol Metabol, 2006;50(4);(705-19).

• 18) Sims N. A., et al.:Regulating DeltaFosB expression in adult Tet-off-DeltaFosB trangenic mice alters bone formation and bone mass. Bone, 2002;30(1);(18-25).

• 19) Windahl S. H., Andersson G., Gustafsson J.:Elucidation of estrogen receptor function in bone with the use of mouse models. TRENDS in Endocrinology & Metabolism, 2002;13;(195-200).

• 20) Dupont S., Krust A., Gansmuller A., Dierich A., Chambon P., Mark M.:Effect of single and compound knockouts of estrogen receptors alpha(ERalpha) and beta(ERbeta) on mouse reproductive phenotypes. Development, 2000;127(19);(4277-91).

• 21) Nakamura T, Imai Y, et al.:Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell, 2007;130(5);(811-23).

• 22) Teitelbaum S. L., Ross F. P.:Genetic regulation of osteoclast development and function. Nature, 2003;4;(638-649).

P.62 掲載の参考文献

• 1) Alberti KGMM, Zimmet PZ for the WHO consultation:Definition, diagnosis and classification of diabetes mellituss and its complications. Part 1:diagnosis and classification of diabetes mellituss. Provisional report of a WHO consultation. Diabet Med 1998, 15;539-553.

• 2) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) JAMA 2001, 285;2486-2497.

• 3) メタボリックシンドローム診断基準検討委員会:メタボリックシンドロームの定義と診断基準. 日本内科学会雑誌 94; 794-809, 2005.

• 4) Nakamura T, Matsuzawa Y:Life-style related disease and adipocytes. Intern Med 41;68-70. 2002.
  pubmed

• 5) Matsuzawa Y, Funahashi T, Kihara S, Shimomura I:Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 24;29-33, 2004.
  pubmed

• 6) Kumada Y, Kihara S, Sumitsuji S, et al.:Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23;85-89, 2003.

• 7) Ohashi K, Ouchi N, Kihara S, et al.:Adiponectin I164T mutation is associated with the metabolic syndrome and coronary artery disease. J Am Coll Cardiol 43;1195-1200, 2004.
  pubmed

• 8) Furukawa S, Fujita T, Shimabukuro M, et al.:Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114;1752-1761, 2004.
  pubmed

• 9) Weisberg SP, McCann D, Desai M, et al.:Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112;1796-1808, 2003.
  pubmed

P.75 掲載の参考文献

• 1) Mancia G, Bousquet P, Elghozi JL, et al.:The sympathetic nervous system and the metabolic syndrome. J Hypertens 2007;25(5);909-20.
  pubmed

• 2) Seals DR, Bell C. Chronic sympathetic activation:consequence and cause of age-associated obesity? Diabetes 2004;53(2);276-84.
  pubmed

• 3) Bachman ES, Dhillon H, Zhang CY, et al.:betaAR signaling required for diet-induced thermogenesis and obesity resistance. Science 2002;297(5582);843-5.
  pubmed

• 4) Jimenez M, Leger B, Canola K, et al.:Beta(1) / beta(2) / beta(3) -adrenoceptor knockout mice are obese and cold-sensitive but have normal lipolytic responses to fasting. FEBS Lett 2002;530(1-3);37-40.
  pubmed

• 5) Clement K, Vaisse C, Manning BS, et al.:Genetic variation in the beta 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. N Engl J Med 1995;333(6);352-4.

• 6) Walston J, Silver K, Bogardus C, et al.: Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the beta 3-adrenergic-receptor gene. N Engl J Med 1995;333 (6);343-7.

• 7) Widen E, Lehto M, Kanninen T, et al.:Association of a polymorphism in the beta 3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns. N Engl J Med 1995;333(6);348-51.
  pubmed

• 8) Kurokawa N, Nakai K, Kameo S, et al.:Association of BMI with the beta 3-adrenergic receptor gene polymorphism in Japanese:meta-analysis. Obes Res 2001;9(12);741-5.
  pubmed

• 9) Zhan S, Ho SC. Meta-analysis of the association of the Trp 64 Arg polymorphism in the beta 3 adrenergic receptor with insulin resistance. Obes Res 2005;13(10);1709-19.

• 10) Small KM, McGraw DW, Liggett SB. Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu Rev Pharmacol Toxicol 2003;43;381-411.
  pubmed

• 11) Sipilainen R, Uusitupa M, Heikkinen S, et al.:Polymorphism of the beta3-adrenergic receptor gene affects basal metabolic rate in obese Finns. Diabetes 1997;46(1);77-80.
  pubmed

• 12) Yoshida T, Sakane N, Umekawa T, et al.:Mutation of beta 3-adrenergic-receptor gene and response to treatment of obesity. Lancet 1995;346(8987);1433-4.
  pubmed

• 13) Shihara N, Yasuda K, Moritani T, et al.:The association between Trp64Arg polymorphism of the beta 3-adrenergic receptor and autonomic nervous system activity. J Clin Endocrinol Metab 1999;84(5);1623-7.
  pubmed

• 14) Yasuda K, Matsunaga T, Adachi T, et al.:Adrenergic receptor polymorphisms and autonomic nervous system function in human obesity. Trends Endocrinol Metab 2006;17(7);269-275.
  pubmed

• 15) Thayer JF, Lane RD. The role of vagal function in the risk for cardiovascular disease and mortality. Biol Psychol 2007;74(2);224-42.
  pubmed

• 16) Piccirillo G, Vetta F, Fimognari FL, et al.:Power spectral analysis of heart rate variability in obese subjects:evidence of decreased cardiac sympathetic responsiveness. Int J Obeselat Metab Disord 1996;20(9);825-9.

• 17) Shihara N, Yasuda K, Moritani T, et al.:Synergistic effect of polymorphisms of uncoupling protein 1 and beta3-adrenergic receptor genes in autonomic nervous system activity. Int J Obes Relat Metab Disord 2001;25(6);761-6.
  pubmed

• 18) Matsumoto T, Miyawaki T, Ue H, et al.:Autonomic responsiveness to acute cold exposure in obese and non-obese young women. Int J Obes Relat Metab Disord 1999;23(8);793-800.
  pubmed

• 19) Fleisher LA, Frank SM, Sessler DI, et al.:Thermoregulation and heart rate variability. Clin Sci(Lond) 1996;90(2);97-103.
  pubmed

• 20) Kogure A, Yoshida T, Sakane N, et al.:Synergicffect of polymorphisms in uncoupling protein 1 and beta3-adrenergic receptor genes on weight loss in obese Japanese. Diabetologia 1998;41(11);1399.
  pubmed

• 21) Sivenius K, Valve R, Lindi V, et al.:Synergistic effect of polymorphisms in uncoupling protein 1 and beta 3-adrenergic receptor genes on long-term body weight change in Finnish type 2 diabetic and non-diabetic control subjects. Int J Obes Relat Metab Disord 2000;24(4);514-9.
  pubmed

• 22) Valve R, Heikkinen S, Rissanen A, et al.:Synergistic effect of polymorphisms in uncoupling protein 1 and beta3-adrenergic receptor genes on basal metabolic rate in obese Finns. Diabetologia 1998;41(3);357-61.
  pubmed

• 23) Kirstein SL, Insel PA. Autonomic nervous system pharmacogenomics:a progress report. Pharmacol Rev 2004;56(1);31-52.
  pubmed

• 24) Leineweber K, Buscher R, Bruck H, et al.:Beta-adrenoceptor polymorphisms. Naunyn Schmiedebergs Arch Pharmacol 2004;369(1);1-22.
  pubmed

• 25) Matsunaga T, Yasuda K, Adachi T, et al.:Association of beta-adrenoceptor polymorphisms with cardiac autonomic modulation in Japanese males. Am Heart J 2007;154(4);759-66.
  pubmed

• 26) Snyder EM, Beck KC, Dietz NM, et al.:Arg 16 Gly polymorphism of the beta 2-adrenergic receptor is associated with differences in cardiovascular function at rest and during exercise in humans. J Physiol 2006;571(Pt 1);121-30.

• 27) Tang W, Devereux RB, Kitzman DW, et al.:The Arg 16 Gly polymorphism of the beta 2-adrenergic receptor and left ventricular systolic function. Am J Hypertens 2003;16(11 Pt 1);945-51.

• 28) Masuo K, Katsuya T, Fu Y, et al.:+{beta}2-and {beta}3-Adrenergic Receptor Polymorphisms Are Related to the Onset of Weight Gain and Blood Pressure Elevation Over 5 Years. Circulation 2005.

• 29) Masuo K, Katsuya T, Fu Y, et al.:Beta 2-adrenoceptor polymorphisms relate to insulin resistance and sympathetic overactivity as early markers of metabolic disease in nonobese, normotensive individuals. Am J Hypertens 2005;18(7);1009-14.
  pubmed

• 30) Brodde OE, Leineweber K. Beta 2-adrenoceptorene polymorphisms. Pharmacogenet Genomics 2005;15(5);267-75.
  pubmed

• 31) Jiang S, Mao G, Zhang S, et al.:Individual and joint association of alpha 1 A-adrenergic receptor Arg347Cys polymorphism and plasma irbesartan concentration with blood pressure therapeutic response in Chinese hypertensive subjects. Clin Pharmacol Ther 2005;78 (3);239-48.
  pubmed

• 32) Snapir A, Koskenvuo J, Toikka J, et al.:Effects of common polymorphisms in the alpha1A-, alpha2B-, beta1-and beta2-adrenoreceptors on haemodynamic responses to adrenaline. Clin Sci (Lond) 2003;104(5);509-20.
  pubmed

• 33) Matsunaga T, Yasuda K, Adachi T, et al.:Alpha-adrenoceptor gene variants and autonomic nervous system function in a young healthy Japanese population. J Hum Genet 2006.

• 34) Finley JC, Jr., O'Leary M, Wester D, et al.:A genetic polymorphism of the alpha 2-adrenergic receptor increases autonomic responses to stress. J Appl Physiol 2004;96(6);2231-9.
  pubmed

• 35) Suzuki N, Matsunaga T, Nagasumi K, et al.:Alpha(2B)-adrenergic receptor deletion polymorphism associates with autonomic nervous system activity in young healthy Japanese. J Clin Endocrinol Metab 2003;88(3);1184-7.
  pubmed

• 36) Heinonen P, Koulu M, Pesonen U, et al.:Identification of a three-amino acid deletion in the alpha2B-adrenergic receptor that is associated with reduced basal metabolic rate in obese subjects. J Clin Endocrinol Metab 1999;84(7);2429-33.
  pubmed

• 37) Sivenius K, Lindi V, Niskanen L, et al.:Effect of a three-amino acid deletion in the alpha2B-adrenergic receptor gene on long-term body weight change in Finnish non-diabetic and type 2 diabetic subjects. Int J Obes Relat Metab Disord 2001;25(11):1609-14.
  pubmed

• 38) Sivenius K, Niskanen L, Laakso M, et al.:A deletion in the alpha 2B-adrenergic receptor gene and autonomic nervous function in centralobesity. Obes Res 2003;11(8);962-70.

• 39) Small KM, Wagoner LE, Levin AM, et al.:Synergistic polymorphisms of beta1-and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 2002;347 (15);1135-42.
  pubmed

• 40) Brede M, Wiesmann F, Jahns R, et al.:Feedback inhibition of catecholamine release by two different alpha 2-adrenoceptor subtypes prevents progression of heart failure. Circulation 2002;106(19);2491-6.

• 41) Small KM, Mialet-Perez J, Seman CA, et al.:Polymorphisms of cardiac presynaptic alpha2C adrenergic receptors:Diverse intragenic variability with haplotype-specific functional effects. Proc Natl Acad Sci USA 2004;101 (35);13020-5.
  pubmed

• 42) Wang JG, Staessen JA. Genetic polymorphisms in the renin-angiotensin system:relevance for susceptibility to cardiovascular disease. Eur J Pharmacol 2000;410(2-3);289-302.

• 43) Nishikino M, Matsunaga T, Yasuda K, et al.:Genetic variation in the Renin-Angiotensin system and autonomic nervous system function in young healthy Japanese subjects. J Clin Endocrinol Metab 2006;91(11);4676-81.
  pubmed

• 44) Agerholm-Larsen B, Nordestgaard BG, Tybjaerg-Hansen A. ACE gene polymorphism in cardiovascular disease:meta-analyses of small and large studies in whites. Arterioscler Thromb Vasc Biol 2000;20(2);484-92.
  pubmed

• 45) Sayed-Tabatabaei FA, Oostra BA, Isaacs A, et al.:ACE polymorphisms. Circ Res 2006;98 (9);1123-33.
  pubmed

• 46) Baudin B. Angiotensin II receptor polymorphisms in hypertension. Pharmacogenomic considerations. Pharmacogenomics 2002;3(1);65-73.
  pubmed

• 47) Hunt SC, Cook NR, Oberman A, et al.:Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension:trials of hypertension prevention, phase II. Hypertension 1998;32(3);393-401.
  pubmed

• 48) Svetkey LP, Moore TJ, Simons-Morton DG, et al.:Angiotensinogen genotype and blood pressure response in the Dietary Approaches to Stop Hypertension (DASH) study. J Hypertens 2001;19(11);1949-56.

• 49) Matsunaga T, Nagasumi K, Yamamura T, et al.:Association of C825T polymorphism of G protein beta 3 subunit with the autonomic nervous system in young healthy Japanese individuals. Am J Hypertens 2005;18(4 Pt 1);523-9.

• 50) Yasuda K, Matsunaga T, Moritani T, et al.:T393C polymorphism of GNAS1 associated with the autonomic nervous system in young, healthy Japanese subjects. Clin Exp Pharmacol Physiol 2004;31(9);597-601.
  pubmed

• 51) Heart rate variability:standards of measurement, physiological interpretation and clinicalse. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 1996;93(5);1043-65.

第2編 食品成分と機能

P.91 掲載の参考文献

• 1) 荒井綜一, 吉川敏一, 金沢和樹ほか: 機能性食品の事典, 朝倉書店, 2007

• 2) 山田耕路: 食品成分のはたらき, 朝倉書店, 2004

• 3) 寺尾純二, 山西倫太郎, 高村仁知, 食品機能学, 光生館, 2003

• 4) Hou Z., Sang S., H. You H. et al.:Mechanism of action of (-)-epigallocatechin-3-gallate:auto-oxidation-dependent inactivation of epidermal growth factor receptor and direct effects on growth inhibition in human esophageal cancer KYSE 150 cells. Cancer Res 2005;65;8049-8056.

• 5) Narasimhan M. L., Coca M. A., Jin J et al.: Osmotin is a homolog of mammalian adiponectin and controls apoptosis in yeast through a homolog of mammalian adiponectin receptor Mol Cell 2005;17;171-180.
  pubmed

• 6) Baba S., Osakabe M., Kato Y. et al:Continuous intake of polyphenolic compounds containing cocoa powder reduces LDL oxidative susceptibility and has beneficial effects on plasma HDL-cholesterol concentrations in humans Am J Clin Nutr 2007;85;709-717.

• 7) Steffen Y., Schewe T., Sies H.:(-)-Epicatechin elevates nitric oxide in endothelial cells via inhibition of NADPH oxidase. Biochem Biophys Res Comm 2007;359;828-833.
  pubmed

• 8) 東敬子, 室田佳恵子, 寺尾純二: 野菜フラボノイドの生体利用性と抗酸化活性, ビタミン 2006; 80; 403-410.
  Medical*Online

• 9) Williamson, G., Barron D., Shimoi K et al.:In vitro biological properties of flavonoid conjugate fsound in vivo. Free Radic Res 2005;39;457-469.
  pubmed

• 10) Sanchez M., Lodi F., Vera R., et al.:Quercetin and isorhamnetin prevent endothelial dysfunction, superoxide production, and overexpresssion of P47 phox induced by angiotensin II in rat aorta. J Nutr 2007;137;910-915.

• 11) Kawai Y., Nishikawa T., Shiba Y., et al.:Macrophage as a target of quercetin glucuronides in human atherosclerotic arteries ; implication in the anti-atherosclerotic mechanism of dietary flavonoids. J Biol Chem In press.

• 12) Baur JA, Pearson K. J., Price N. L. et al.:Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444;337-342(2006)

• 13) Tachibana H., Koga K., Fijimura Y et al.:A receptor for green tea polyphenol EGCG. Nature Struct Mol Biol 2004;11;380-381.

• 14) 寺尾純二, 芦田均: 機能性ポリフェノール, 化学と生物 2006; 44; 688-698.

• 15) Zhang Y., Kensler T. W., Cho C.-G. et al.:Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates Proc Natl Acad Sci USA 1994;91;3147-3150.
  pubmed

• 16) Morimitsu Y., Hayashi K., Nakagawa Y., et al.:Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates Biofactors 2000;13;271-276.

P.106 掲載の参考文献

• 1) Bettuzzi S. et al.:Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia : a preliminary report from a one-year proof-of-principle study. Cancer Res 2006;66;1234-1240.
  pubmed

• 2) Chow H-H. et al.:Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res 2003;9;3312-3319.
  pubmed

• 3) Kim S. et al.:Plasma and tissue levels of tea catechins in rats and mice during chronic consumption of green tea polyphenols:Nutr Cancer 2000;37;41-48.
  pubmed

• 4) Garbisa S. et al.:Tumor invasion:molecular shears blunted by green tea. Nat Med 1999;5;1216.
  pubmed

• 5) Dell 'Aica I et al.:Potent inhibitors of anthrax lethal factor from green tea. EMBO Rep 2004;5;418-422.
  pubmed

• 6) Nam S. et al.:Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem 2001;276;13322-13330.
  pubmed

• 7) Sah J. F. et al.:Epigallocatechin-3-gallate inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of ERK1/2 and AKT kinases. J Biol Chem 2004;279;12755-12762.
  pubmed

• 8) Fang M. Z. et al.:Tea poluphenol (-)-epigallocatechin 3-gallate inhibits DNA methyltrabsferase and reactivities methylation-silenced genes in cancer cell lines. Cancer Res 2003;63;7563-7570.

• 9) Leone M. et al.:Cancer prevention by tea polyphenols is liked to their direct inhibition of antiapoptotic Bcl-2-family proteins. Cancer Res 2003;63;8118-8121.

• 10) Ermakova S. et al.:The intermediate filament protein vimentin is a new target for epigallocatechin gallate. J Biol Chem ;2005;280;16882-16890.
  pubmed

• 11) Hou Z. et al.:Effects of tea polyphenols on signal transduction pathways related to cancer chemoprevention. Mutat Res 2004;555;3-19.
  pubmed

• 12) Hou Z. et al.:Mechanism of action of (-) -pigallocatechin-3-gallate:auto-oxidation-dependent inactivation of epidermal growth factor receptor and direct effects on growth inhibition in human esophageal cancer KYSE 150 cells. Cancer Res 2005;65;8049-8056.

• 13) Menard S. et al.:New insights into the metastasis-associated 67 kD laminin receptor. J Cell Biochem 1997;67;155-165.
  pubmed

• 14) Chen J. et al.:The laminin receptor modulates granulocyte-macrophage colony-stimulating factor receptor complex formation and modulates its signaling. Proc Natl Acad Sci USA 2003;100;14000-14005.
  pubmed

• 15) Chen A.:The neuropeptides GnRH-II and GnRH-I are produced by human T cells and trigger laminin receptor gene expression, adhesion, chemotaxis and homing to specific organs. Nat Med 2002;1421-1426.

• 16) Gauczynski S. et al.:The 37-kDa/67-kDa laminin receptor acts as the cell-surface receptor for the cellular prion protein. EMBO J 2001;20;5863-5875.
  pubmed

• 17) Wang K. S. et al.:High-affinity laminin receptor is a receptor for Sindbis virus in mammaliane clls. J Virol 1992;66;4992-5001.

• 18) Akache B. et al.:The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8,2,3, and 9. J Virol 2006;80;9831-9836.
  pubmed

• 19) Thepparit C. et al.:Serotype-specific entry of gengue virus into liver cells:identification of the 37-kilodalton/67-kilodalton high-affinity laminin receptor as a dengue virus serotype 1 receptor. J Virol 2004;78;12647-12656.
  pubmed

• 20) Simons K. et al.:Functional rafts in cell membranes. Nature 1997;387, 569-572.
  pubmed

• 21) Fujimura Y. et al.:Lipid raft-associated catechin suppresses the FcεRI expression by inhibiting phosphorylation of the extracellular signal-regulated kinase1/2. FEBS Lett 2004;556;204-210.

• 22) Tachibana H. et al.:A receptor for green tea polyphenol EGCG. Nat Struct Mol Biol 2004;11;380-381.
  pubmed

• 23) Fujimura Y. et al.:A lipid raft-associated 67 kDa laminin receptor mediates suppressive effect of epigallocatechin-3-O-gallate on FcεRI expression. Biochem Biophys Res Commun 2005;333;628-635.

• 24) Umeda D. et al.:Green tea polyphenol EGCG signaling pathway through 67-kDa laminin receptor. J Biol Chem 2008;283;3050-3058.
  pubmed

• 25) Novak K.:Tea time. Nat Reviews Cancer 2004;4;251.

• 26) Iwasaki T. et al.:Diphosphorylated MRLC is required for organization of stress fibers in interphase cells and the contractile ring in dividing cells. Cell Struct. Funct 2001;26;677-683.
  pubmed

• 27) Umeda D. et al.:Epigallocatechin-3-O-gallate disrupts stress fibers and the contractile ring by reducing myosin regulatory light chain phosphorylation mediated through the target molecule 67kDa laminin receptor. Biochem Biophys Res Commun 2005;336;674-681.

• 28) Shammas M. A. et al.:Specific killing of multiple myeloma cells by (-) -epigallocatechin-3-gallate extracted from green tea:Biological activity and therapeutic implication. Blood 2006;108;2804-2810.
  pubmed

• 29) Revera J.:Molecular adapters in Fc (epsilon) RI signaling and the allergic response. Curr Opin Immunol 2002;14;688-693.

• 30) Fujimura Y. et al.:The involvement of the 67 kDa laminin receptor-mediated modulation of cytoskeleton in the degranulation inhibition induced by epigallocatechin-3-O-gallate. Biochem Biophys Res Commun 2006;348;524-531.
  pubmed

• 31) Fujimura Y. et al.:A tea catechin suppresses the expression of the high affinity IgE receptor FcεRI in the human basophilic KU812 cells. J Agric Food Chem 2001;49;2527-2531.

• 32) Sano M. et al.:Novel antiallergic catechin derivatives isolated from oolong tea. J Agric Food Chem 1999;47;1906-1910.

• 33) Tachibana H. et al.:Identification of a methylated epigallocatechin gallate as an inhibitor of degranulation in human basophilic KU812 cells. Biosci Biotech Biochem 2000;64;452-454.

• 34) Maeda-Yamamoto M. et al.:In vitro and in vivo anti-allergic effects of 'benifuuki' green tea containing O-methylated catechin and ginger extract enhancement. Cytotechnology in press.

• 35) Maeda-Yamamoto M. et al.:O-methylated catechins from tea leaves inhibit multiple protein kinases in mast cells. J Immunol 2004;172;4486-4492.
  pubmed

• 36) 安江正明ら: 通年性アレルギー性鼻炎患者を対象とした「べにふうき」緑茶の抗アレルギー作用並びに安全性評価. 日本臨床栄養学会誌 2005; 27; 33-51.

• 37) Fujimura Y. et al.:Antiallergic tea catechin, (-) -Epigallocatechin-3-O- (3-O-methyl) gallate, suppresses FcεRI expression in human basophilic KU812 cells. J Agric Food Chem 2001;50;5729-5734.

• 38) Fujimura Y. et al.:The 67kDa laminin receptor as a primary determinant of anti-allergic effects of O-methylated EGCG. Biochem Biophys Res Commun 2007;364;79-85.

• 39) Tachibana H. et al.:Identification of an inhibitor for interleukin 4-induced ε germline transcription and antigen-specific IgE productionin vivo. Biochem Biophys Res Commun 2001;280;53-60.

P.116 掲載の参考文献

• 1) 八村敏志: 経口免疫寛容現象の機構追究. 炎症と免疫 2006; 14; 752-758

• 2) Asai K, Hachimura S, Kimura M, et al.:T cell hyporesponsiveness induced by oral administration of ovalbumin is associated with impaired NFAT nuclear translocation and p27 kip 1 degradation. J Immunol. 2002;169;4723-4731

• 3) Kaji T, Hachimura S, Ise W, et al.:Proteome analysis reveals caspase activation in hyporesponsive CD4 T lymphocytes induced in vivo by the oral administration of antigen. J Biol Chem. 2003;278;27836-27843

• 4) Ise W, Nakamura K, Shimizu N, et al.:Orally tolerized T cells can form conjugates with APCs but are defective in immunological synapse formation. J Immunol. 2005;175;829-838

• 5) Bjorksten B, Sepp E, Julge K, et al.:Allergy development and the intestinal microflora duringhe first year of life. J. Allergy Clin. Immunol. 2001;108;516-520

• 6) Kalliomaki M, Salminen S, Arvilommi H, et al.: Probiotics in primary prevention of atopic disease:a randomised placebo-controlled trial. Lancet 2001;357;1076-1079

• 7) Murosaki S, Yamamoto Y, Ito K, et al.:Heatkilled Lactobacillus plantarum L-137 suppresses naturally fed antigen-specific IgE production by stimulation of IL-12 production in mice. J. Allergy Clin. Immunol. 1998;102;57-64

• 8) Shida, K., Makino, K., Morishita, A. et al..: Lactobacillus casei inhibits antigen-induced IgE secretion through regulation of cytokine production in murine splenocyte cultures. Int. Arch. Allergy Immunol. 1998;115;278-287

• 9) Fujiwara D, Inoue S, Wakabayashi H, et al.: The anti-allergic effects of lactic acid bacteria are strain dependent and mediated by effects on both Th1/Th2 cytokine expression and balance. Int Arch Allergy Immunol. 2004;135;205-15

• 10) H. Kanzato, S. Fujiwara, W. Ise, S. et al.: Lactobacillus acidophilus strain L-92 induces apoptosis of antigen-stimulated T cells. Immunobiology 印刷中

• 11) Nagura, T., Hachimura, S., Hashiguchi, M. et al.:Suppressive Effect of Dietary Raffinose on T-helper 2 cell-mediated immunity. Br. J. Nutr. 2002;88;421-426

• 12) Tomita, K., Nagura, T., Okuhara, Y. et al.:Dietary melibiose regulates Th cell response and enhances the induction of oral tolerance. Biosci Biotechnol Biochem. 2007;71;-2774-2780

• 13) Koizumi T, Bando N, Terao J, Yamanishi R.:Feeding with both beta-carotene and supplementl allpha-tocopherol enhances type 1 helper T cell activity among splenocytes isolated from DO11.10 mice. Biosci Biotechnol Biochem. 2006;703042-5

• 14) Nagafuchi S, Hachimura S, Totsuka M et al.:Dietary nucleotides up-regulate antigen-specific Th1 immune responses and suppress antigen-specific IgE responses in mice. Int. Arch. Allergy Immunol. 122;33-41;2000

• 15) Fujimura Y, Umeda D, Kiyohara Y, et al.:Thenvolvement of the 67 kDa laminin receptor mediated modulation of cytoskeleton in the degranulationnhibition induced by epigallocate chin-3-O-gallate. Biochem Biophys Resommun. 348+ADs-524-31+ADs-2006

• 16) 大草敏史, 佐藤信紘: プロバイオティクスとバイオジェニクス(伊藤喜久治編). NTS; 2005; 72-86

• 17) Sato, A., Hashiguchi, M., Toda, E., et al..: CD11b+ Peyer's patch dendritic cells secrete IL-6 and induce IgA secretion from naive B cells. J. Immunol. 2003;171;3684-3690

• 18) Kuraoka, M., Hashiguchi, M., Hachimura, S., et al.:CD4-c - kit-CD3ε-IL-2Rα+ Peyer's patch cells are a novel cell subset which secrete IL-5 in response to IL-2:implications for their role in IgA production. Eur. J. Immunol. 2004;34;1920-1929

• 19) Mora JR, Iwata M, Eksteen B, et al.: Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells. Science. 2006;314;1157-60

• 20) He B, Xu W, Santini PA, et al.:Intestinal bacteria trigger T cell-independent immunoglobulin A (2) class switching by inducing epithelialcell secretion of the cytokine APRIL. Immunity. 2007;26;812-26

• 21) Tezuka H, Abe Y, Iwata M, et al.:Regulationf IgA production by naturally occurring TNF/iNOS-producing dendritic cells. Nature. 2007;448;929-33

• 22) Yasui H, Kiyoshima J, Hori T, Shida K.: Protection against influenza virus infection of mice fed Bifidobacterium breve YIT4064. Clin Diagn Lab Immunol. 1999;6;186-92

• 23) Hosono, A., Ozawa, A., Kato, R. et al.:Dietary fructooligosaccharides induce immunoregulation of intestinal IgA secretion by murine Peyer's patch cells. Biosci. Biotechnol. Biochem. 2003;67;758-764

• 24) Nakamura, Y., Nosaka, S., Suzuki, M. et al.:Dietary fructooligosaccharides up-regulate immunoglobulin A response and polymeric immunoglobulin receptor expression in intestines of infant mice. Clin. Exp. Immunol. 2004;137;52-58.
  pubmed

• 25) Nagafuchi S, Totsuka M, Hachimura S, et al.:Dietary nucleotides increase the mucosal IgA response and the secretion of transforming growth factor β from intestinal epithelial cells in mice. Cytotechnology, 2002;40;49-58

• 26) Kaminogawa S. and M. Nanno:Modulation of immune functions by foods. eCAM, 2004;1;241-250

P.126 掲載の参考文献

• 1) D. P. Strachan;Br. Med. J., 299;259;1989

• 2) 中村晋, 飯倉洋治 編: 最新食物アレルギー, 永井書店, 2002

• 3) 岸野泰男, 菅野道廣編: 食物アレルギー, 光生館, 1995

• 4) 上野川修一, 近藤直実 編: 食品アレルギー対策ハンドブック, サイエンスフォーラム, 1996

• 5) 近藤康人: 臨床栄養 106; 444; 2005
  Medical*Online

• 6) Yagami T.:Allergies to cross-reactive plant proteins. Latex-fruit syndrome is comparable with pollen-food allergy syndrome. Int Arch Allergy Immunol. 128;271-9;2002

• 7) Eriksson NE, Formgren H, Svenonius E:Birch pollen-related food hyper-sensitivity:influence of total and specific IgE levels. A multicenter study. Allergy 38;353-7;1983

• 8) 小川正: 食品アレルギーを誘発する植物起源アレルゲン, 化学と生物, 40; 643-652; 2002

• 9) Ogawa T, Tsuji H, Bando N, Kitamura K, Yue-Lin Z, Hirano H, Nishikawa K.:Identification of the soybean allergenic protein, Gly m Bd 30k, with the soybean seed 34-kDa oil-body-associated protein. Biosci Biotech Biochem 57;1030-3;1993

• 10) Ogawa T, Bando N, Tsuji H, Nishikawa K, Kitamura K.:α-Subunit of β-conglycinin, an allergic protein recognized by IgE antibodies of soybean-senseitive patients with atopic dermatitis. Biosci Biotech Biochem;59;831-3;1995

• 11) 井戸敏子, 若原真美, 徳力篤, 長谷川美紀, 清原隆宏, 熊切正信, 森山達哉:「豆乳摂取後にアナフィラキシーを生じた2例」 皮膚科の臨床 48巻, (6); 777-780; 2006

• 12) 原田晋, 中村晶子, 松永亜紀子, 飯島麻耶, 吉崎仁胤, 斎藤研二, 足立厚子, 森山達哉: 「豆乳アレルギーの3例」 日本皮膚アレルギー・接触皮膚炎学会雑誌 1; p.31-38; 2007

• 13) 福田恭子, 落合豊子, 相川美和, 東郷香奈, 豊田康之, 森山達哉: 「大豆による口腔アレルギー症候群-カバノキアレルギーとの関連と交差反応性抗原の解析」 日本皮膚アレルギー・接触皮膚炎学会雑誌 2; p.124-130; 2007

• 14) Kleine-Tebbe J, Wangorsch A, Vogel L, Crowell DN, Haustein UF, Vieths S.:Severe oral allergy syndrome and anaphylactic reactions caused by a Bet v1-related PR-10 protein in soybean, SAM22. J Allergy Clin Immunol 110;797-804;2002

• 15) Rihs HP, Chen Z, Rueff F, Petersen A, Rozynek P, Heimann H, Baur X.:IgE binding of the recombinant allergen soybean profilin (rGly m3) is mediated by conformational epitopes. J Allergy Clin Immunol:104;1293-301;1999

• 16) Moroz LA, Yang WH.:Kunits soybean trypsin inhibitor A specific allergen in food anaphylaxis. New Eng J MED;302;1126-8;1980

• 17) Moriyama T ら, 論文準備中

• 18) Moriyama T, Machidori M, Ozasa S, Maebuchi M, Urade R, Takahashi K, Ogawa T, Maruyama N.:A novel enzyme-linked immunosorbent assay for quantification of soybean beta-conglycinin, a major soybean storage protein, in soybean and soybean food products. J Nutr Sci Vitaminol (Tokyo). ;51(1);34-9;2005

• 19) 小川正: 低アレルゲン大豆品種(ゆめみのり)の創出と加工食品の開発, 食品工業, 45, 14; 1-10; 2002

P.136 掲載の参考文献

• 1) Muramatsu K., Fukuyo M., Hara Y. et al.: Effect of green tea catechins on plasma cholesterol level in cholesterol-fed rats. J Nutr Sci Vitaminol 1986;32;613-622.
  pubmed

• 2) 福與真弓, 原征彦, 村松敬一郎: 茶葉カテキンの構成成分である(-)エピガロカテキンガレートの血中コレステロール低下作用. 栄食誌, 1986; 39; 495-500.

• 3) Matsuda H., Chisaka T., Kubomura Y. et al.:Effects of crude drugs on experimental hypercholesterolemia. I. Tea and its active principles. J Ethnopahrmacol 1986;17;213-224.
  pubmed

• 4) Chisaka T., Matsuda H., Kubomura Y. et al.:he effect of crude drugs on experimental hypercholesteremia:ode of action of(-)-epigallocatechinallate in tea leaves. Chemharm Bull 1988;36;227-233.

• 5) Ikeda I., Imasato Y., Sasaki E. et al.:Tea catechins decrease micellar solubility and intestinal absorption of cholesterol in rats. Biochim Biophys Acta 1992;1127;141-146.
  pubmed

• 6) Ikeda I., Kobayashi M., Hamada T. et al.: Heatepimerized tea catechins rich in gallocatechin gallate and catechin gallate are more effective to inhibit cholesterol absorption than tea catechins rich in epigallocatechin gallate and epicatechin gallate. J Agric Food Chem 2003;51;7303-7307.

• 7) Kobayashi M., Unno T., Suzuki Y. et al.:Heatepimerized tea catechins have the same cholesterol-lowering activity as green tea catechins in cholesterol-fed rats. Biosci Biotechnol Biochem 2005;69;2455-2458.
  pubmed

• 8) 鈴木裕子, 小林誠, 海野知紀ほか: 高脂肪食飼育ハムスターにおけるガレート型カテキンの脂質代謝改善作用. 日本食品科学工学会誌 2005; 52; 167-171.

• 9) Kajimoto O., Kajimoto Y., Yabune M. et al.: Tea catechins reduce serum cholesterol levels in mild and borderline hypercholesterolemia patients. J Clin Biochem Nutr 2003;33;101-111.

• 10) 梶本修身, 梶本佳孝, 武田雅也ほか: 女性を対象とした長期摂取におけるガレート型カテキン配合飲料の血清コレステロール低下作用. Health Sci 2006; 22; No.1; 60-71.

• 11) Ikeda I., Tsuda K., Suzuki Y. et al.:Tea catechins with a galloyl moiety suppress postprandial hypertriacylglycerolemia by delaying lymphatic transport of dietary fat in rats. J Nutr 2005;135;155-159.
  pubmed

• 12) Unno T., Tago M., Suzuki Y. et al.: Effect of tea catechins on postprandial plasma lipid responses in human subjects. Brit J Nutr 2005;93;543-547.
  pubmed

• 13) 海野知紀, 鈴木裕子, 野澤歩ほか: 茶カテキンによる脂肪摂取後の血中中性脂肪上昇抑制効果. 栄養-評価と治療 2005; 22; 207-212.
  Medical*Online

• 14) Meguro S., Mizuno T., Onizawa K. et al.:Effects of tea catechins on diet-induced obesity in mice. J Oleo Sci 2001;50;593-598.

• 15) Hase T., Komine Y., Meguro S. et al.:Antiobesity effects of tea catehicns in humans. J Oleo Sci 2001;50;599-605.

• 16) Nagao T., Meguro S., Soga S. et al.:J Oleo Sci 2001;50;717-728.

• 17) Kajimoto O., Kajimoto Y., Yabune M. et al.: Tea catechins with a galloyl moiety reduce body weight and fat. J Health Sci 2005;51;161-171.

• 18) Ikeda I., Hamamoto R., Uzu K. et al.:Dietary gallate esters of tea catechins reduce deposition of visceral fat, hepatic triacylglycerol, and activities of hepatic enzymes related to fatty acid synthesis in rats. Biosci Biotechnol Biochem 2005;69;1049-1053.
  pubmed

• 19) Osaki N., Harada U., Watanabe H. et al.:Effect of tea catechins on energy metabolism in rats. J Oleo Sci 2001;50;677-682.

• 20) Onizawa K., Watanabe, H., Yamaguchi T. et al.: Effect of tea catechins on the oxidation of dietary lipids in rats. J Oleo Sci 2001;50;657-662.

• 21) Harada U., Chikama A., Saito S. et al.:Effects of the long-term ingestion of tea catechins on energy expenditure and dietary fat oxidation in healthy subjects. J Health Sci 2005;51;248-252.

• 22) Murase T., Nagasawa A., Suzuki J. et al.:Beneficial effects of tea catechins on diet-induced obesity:stimulation of lipid catablism in the liver. Inter J Obesity 2002;26;145-1464.

• 23) Kuriyama S., Shimazu T., Ohmori K. et al.:Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan. JAMA 2007;296;1255-1265.

P.149 掲載の参考文献

• 1) Levi-montalcini R., Hamburger V.:Selective growth stimulating effects of mouse sarcoma on the sensory and sympathetic nervous system of the chick embryo. J Exp Zool 1951;116;321-361.
  pubmed

• 2) Barde YA., Edgar D., Thoenen H.:Purification of a new neurotrophic factor from mammalian brain. EMBO J 1982;1;549-553.
  pubmed

• 3) Hohn A., Leibrock J., Bailey K. et al.:Identification and characterization of a novel member of the nerve growth factor/brain-derived neurotrophic factor family. Nature 1990;44;339-341.

• 4) Hallbook F., Ibanez CF., Persson H.:Evolutionary studies of the nerve growth factor family reveal a novel member abundantly expressed in Xenopus ovary. Neuron 1991;6;845-858.
  pubmed

• 5) Berkemeier LR., Winslow JW., Kaplan DR. et al.: Neurotrophin-5:a novel neurotrophic factor that activates trk and trkB. Neuron 1991;7;857-866.
  pubmed

• 6) Ip NY., Ibanez CF., Nye SH. et al.:Mammalian neurotrophin-4:structure, chromosomal localization, tissue distribution, and receptor specificity. Proc Natl Acad Sci USA 1992;89;3060-3064.
  pubmed

• 7) Huang EJ., Reichardt LF.:Trk receptors:Roles in neuronal signal transduction. Annu. Rev. Biochem 2003;72;609-642.
  pubmed

• 8) Greene LA., Tischler AS.:Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci USA 1976;73;2424-2428.
  pubmed

• 9) Cunningham M., Greene LA.:A function-structure model for NGF-activated TRK. The EMBO J 1998;17;7282-7293.
  pubmed

• 10) Morooka T., Nishida E.:Requirement of p38 mitogen-activated protein kinase for neuronal differentiation in PC12 cells. J Biol Chem 1998;273;24285-24288.
  pubmed

• 11) Xiao J., Liu Y.:Differential roles of ERK and JNK in early and late stages of neuritogenesis:a study in a novel PC12 model system. J Neurochem 2003;86;1516-1523.

• 12) York RD., Yao H., Dillon T. et al.: Rap1 mediates sustained MAP kinase activation induced by nerve growth factor. Nature 1998;392;622-626.
  pubmed

• 13) Price R. D., Milne S. A., Sharkey J. et al.:Advancesin small molecules promoting neurotrophic function. Pharmacol Ther 2007;115;292-306

• 14) Olson L., Nordberg A., von Holst H. et al.:Nerve growth factor affects 11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (case report). J Neural Transm Park Dis Dement Sect 1992;4;79-95.

• 15) Eriksdotter Jonhagen M., Nordberg A., Amberla K. et al.:Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord 1998;9;246-257.
  pubmed

• 16) Kordower JH., Palfi S., Chen EY. et al.:Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment ina patient with Parkinson's disease. Ann Neurol 1999;46;419-424.

• 17) ALS CNTF Treatment Study Group:A doubleblind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology 1996;46;1244-1249.

• 18) Dawbarn D., Allen SJ.:Neurotrophins and neurodegeneration. Neuropathol Appl Neurobiol 2003;29;211-230.
  pubmed

• 19) Beglova N., LeSauteur L., Ekiel I. et al.: Solution structure and internal motion of a bioactive peptide derived from nerve growth factor. J Biol Chem 1998;273;23652-23658.
  pubmed

• 20) Soh Y., Kim J. A., Sohn N. W. et al.:Protective Effects of Quinic Acid Derivatives on Tetrahydropapaveroline-Induced Cell Death in C6 Glioma Cells. Biol Pharm Bull 2003;26;803-7.
  pubmed

• 21) Hur J. Y., Soh Y., Kim B. H. et al.:Neuroprotective and Neurotrophic Effects of Quinic Acids from Aster scaber in PC12 Cells. Biol Pharm Bull 2001;24;921-4.
  pubmed

• 22) Qi J., Ojika M., Sakagami Y.:Neuritogenic Cerebrosides from an Edible Chinese Mushroom. Part 2y:Structures of Two Additional Termitomycesphins and Activity Enhancement of an Inactive Cerebroside by Hydroxylation. Bioorg Med Chem 2001;9;2171-7.

• 23) Pradines A., Magazin M., Schiltz P. et al.:Evidence for nerve growth factor-potentiating activities of the nonpeptidic compound SR 57746A in PC12 cells. J Neurochem 1995;64;1954-64.
  pubmed

• 24) Lee F. S., Rajagopal R., Chao M. V.:Distinctive features of Trk neurotrophin receptor transactivation by G protein-coupled receptors. Cytokine Growth Factor Rev 2002;13;11-7.
  pubmed

• 25) Arrieta O., Garcia-Navarrete R., Zuniga S. et al.:Retinoic acid increases tissue and plasmacontents of nerve growth factor and prevents neuropathy in diabetic mice. Eur J Clin Invest 2005;35;201-207.
  pubmed

• 26) Baranes D., Lederfein D., Huang, Y. Y., et al.:Tissue plasminogen activator contributes to the late phase of LTP and to synaptic growth in the hippocampal mossy fiber pathway. Neuron 1998;21;813-825.

• 27) Shimbo, M., Kawagishi, H., and Yokogoshi, H.:Erinacine A increases catecholamine and nerve growth factor content in the central nervous system of rats. Nutr Res 2005;25;617-623.

• 28) Salim K. N., McEwen B. S., Chao H. M.:Ginsenoside Rb 1 regulates ChAT, NGF and trkA mRNA expression in the rat brain. Brain Res Mol Brain Res 1997;47;177-82.

• 29) Rudakewich M., Ba F., Benishin C. G.:Neurotrophic and neuroprotective actions of ginsenosides Rb(1) and Rg(1). Planta Med 2001;67;533-7.
  pubmed

• 30) Yabe T., Tuchida H., Kiyohara H.:Induction of NGF synthesis in astrocytes by onjisaponins of Polygala tenuifolia, constituents of Kampo (Japanese herbal) medicine, Ninjin-Yoei- To. Phytomedicine 2003;10;106-14.
  pubmed

• 31) Price R. D., Yamaji T., Matsuoka N.:FK 506 potentiates NGF-induced neurite outgrowth via the Ras/Raf/MAP kinase pathway. Br J Pharmacol 2003;140;825-9.
  pubmed

• 32) Tanaka K., Fujita N., Ogawa N.:Immunosup pressive (FK 506) and non-immunosuppressive (GPI1046) immunophilin ligands activate neurotrophic factors in the mouse brain. Brain Research 2003;970;250-253.

• 33) 村形力, 松田譲: バイオプローブ, K252aからの神経変成疾患治療薬への展開(バイオプローブ), BIOINDUSTRY 1998; 15; 43-49.

• 34) Roux P. P., Dorval G., Boudreau M. et al.:K252a and CEP1347 Are Neuroprotective Compounds That Inhibit Mixed-lineage Kinase-3 and In duce Activation of Akt and ERK. J Biol Chem 2002;277;49473-80.

• 35) Shigeta K., Ootaki K., Tatemoto H. et al.: Potentiation of Nerve Growth Factor-Induced Neurite Outgrowth in PC 12 Cells by a Coptidis Rhizoma Extract and Protoberberine Alkaloids. Biosci Biotechnol Biochem 2002;66;2491-4.

• 36) Li Y., Ishibashi M., Chen X. et al.:Littorachalcone, a New Enhancer of NGF-Mediated Neurite Outgrowth, from Verbena littoralis. Chem Pharm Bull(Tokyo) 2003;51;872-4.
  pubmed

• 37) Jung K. M., Park K. S., Oh J. H.: Activation of p38 Mitogen-Activated Protein Kinase and Activator Protein-1 during the Promotion of Neurite Extension of PC-12 Cells by 15-Deoxy-delta-12, 14-prostaglandin J2. Mol Pharmacol 2003;63;607-16.
  pubmed

• 38) Fahey J. W., Zalcmann A. T., Talalay P.:The chemical diversity and distribution of glucosinolates and isothiocyanates among plants. Phytochemistry 2001;56;5-51.
  pubmed

• 39) Tang C. S., Tang W. J.:Inhibition of papain by isothiocyanates. Biochim Biophys Acta. 1976;452;510-20.
  pubmed

• 40) Morimitsu Y., Nakagawa Y., Hayashi K. et al.:A sulforaphane analogue that potently activatesthe Nrf2-dependent detoxification pathway. J Biol Chem 2003;277;3456-63.

• 41) Dinkova-Kostova AT., Holtzclaw W. D. Cole, R. N. et al.:Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating inductionof phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci USA 2002;99;11908-13.

• 42) van Montfort R. L., Congreve M., Tisi D., et al.:Oxidation state of the active-site cysteine in protein tyrosine phosphatase 1B. Nature 2003;423;773-7.
  pubmed

• 43) Salmeen A., Andersen J. N., Myers M. P., et al.:Redox regulation of protein tyrosine phosphatase 1B involves a sulphenyl-amide intermediate. Nature 2003;423;769-73.
  pubmed

P.164 掲載の参考文献

• 1) 清水昌: C20高度不飽和脂肪酸含有 Single Cell Oilの生産. 農芸化学会誌, 1995; 69; 707-715.

• 2) Certik M., Sakuradani E., Shimizu S.:Desaturase defective fungal mutants:useful tools for the regulation and overproduction of polyunsaturated fatty acids. Trends Biotechnol, 1998;16;500-505.

• 3) 藤川茂昭, 東山堅一, 清水昌: 糸状菌によるアラキドン酸含有油脂の発酵生産. バイオサイエンスとインダストリー, 1999; 57; 818-821.

• 4) Shimizu S., Ogawa J.: Oils, microbial production. In:Encyclopedia of Biprocess Technology:Fermentation, Biocatalysis, and Bioseparation. Flickinger M. C., Drew S. W. (eds.), John Wiley & Sons, New York, 1999, p1839-1851.

• 5) 清水昌, 小川順, 櫻谷英治: 有用油脂生産微生物の代謝工学. バイオサイエンスとインダストリー, 2001; 59; 451-454.

• 6) Ogawa J., Sakuradani E., Shimizu S.: Production of C20 polyunsaturated fatty acids by an arachidonic acid-producing fungus Mortierella alpina 1S-4 and related starins. In:Lipid Biotechnology. Kuo, T. M., Gardner H. W. (eds.) Marcel Dekker, New York, 2002, p563-574.

• 7) 清水昌, 櫻谷英治, 小川順: 機能性脂質の微生物生産-アラキドン酸関連高度不飽和脂肪酸含有油脂および共役脂肪酸の生産を中心として-. オレオサイエンス, 2003; 3; 129-139.

• 8) 小川順, 櫻谷英治, 清水昌: 機能性脂質の分子設計. 機能性脂質のフロンティア (佐藤清隆, 柳田晃良, 和田俊 監修), シーエムシー出版, 2004, p77-85.

• 9) 小川順, 櫻谷英治, 清水昌: 機能性脂質の微生物生産. 生物工学会誌, 2005; 83; 339-341.

• 10) Pariza M. W., Park Y., Cook M. E.:The biologically active isomers of conjugated linoleic acid. Prog Lipid Res, 2001;40;283-98.
  pubmed

• 11) Kepler C. R., Hirons K. P., McNeill J. J. et al.:Intermediates and products of the biohydrogenation of linoleic acid by Butyrinvibrio fibrisolvens. J Biol Chem, 1966;241;1350-1354.
  pubmed

• 12) Kishino S., Ogawa J., Omura Y. et al.:Conjugated linoleic acid production from linoleic acid by lactic acid bacteria. J Am Oil Chem Soc, 2003;79;159-163.

• 13) Kishino S., Ogawa J., Ando A. et al.:tructural analysis of conjugated linoleic acid produced by Lactobacillus plantarum, and factors affecting isomer producton. Biosci Biotechnol Biochem, 2003;67;79-182.

• 14) Ogawa J., Matsumura K., Kishino S. et al.:Conjugated linoleic acid accumulation via 10-hydroxy-12-octadecaenoic acid during microaerobic transformation of linoleic acid by Lactobacillus acidophilus. Appl Environ Microbiol, 2001;67;1246-1252.
  pubmed

• 15) Kishino S., Ogawa J., Ando A. et al.:Ricinoleic acid and castor oil as substrates for conjugated linoleic acid production by washed cells of Lactobacillus plantarum. Biosci Biotechnol Biochem, 2002;66;2283-2286.
  pubmed

• 16) Ando A., Ogawa J., Kishino S. et al.:CLA production from ricinoleic acid by lactic acid bacteria. J Am Oil Chem Soc, 2003;80;889-894.

• 17) Ando A., Ogawa J., Kishino S. et al.:Conjugated linoleic acid production from castor oil by Lactobacillus plantarum JCM 1551. Enzyme Microb Technol, 2004;35;40-45.

• 18) 小川順, 櫻谷英治, 清水昌: 微生物による機能性脂質の生産. 科学と工業, 2002; 76; 163-170.

• 19) 小川順, 岸野重信, 清水昌: 微生物による共役リノール酸(CLA)生産. バイオサイエンスとインダストリー, 2002; 60; 753-754.

• 20) Ogawa J., Kishino S., Ando A. et al.: Production of conjugated fatty acids by lactic acid bacteria. J Biosci Bioeng, 2005;100;355-364.
  pubmed

• 21) Kishino S., Ogawa J., Ando A. et al.: Conjugated α-linolenic acid production from α-linolenic acid by Lactbacillus plantarum AKU 1009a. Eur J Lipid Sci Technol, 2003;105;572-577.

• 22) Riva S.:Laccases:blue enzymes for green chemistry. Trends Biotechnol, 2006;24;219-226.
  pubmed

• 23) Bladrian P.:Fungal laccases-occurrence and properties. FEMS Microbiol Rev ; 2006;30;215-242.

• 24) 小川順: お口の恋人 "酵素". 生物工学会誌, 2004; 82; 70-71.

• 25) 小川順, 清水昌: 機能性食品・栄養補助食品としての酵素利用と醸造微生物. 日本醸造協会誌, 2004; 99; 832-849.

• 26) G. Leed:Health and legal aspects of the use of enzymes. In:Enzymes in Food Processing. 2nd ed, Leed G. (ed), Academic Press, New York, 1975, p549-554.

• 27) Boss G. R., Seegmiller J. E.:Hyperuricemia and gout. Classification, complications and management. N Engl J Med, 1979;300;1459-68.
  pubmed

• 28) Chiang H. C., Lo Y. J., Lu F. J.: Xanthine oxidase inhibitors from the leaves of Alsophila spinulosa (Hook) Tryon. J Enzyme Inhib, 1994;8;61-71.

• 29) Owen P. L., Johns T.:Xanthine oxidase inhibitory activity of northeastern North American plant remedies used for gout. J Ethnopharmacol, 1999;64;149-160.

• 30) Nguyen M. T., Awale S., Tezuka Y. et al.:Hypouricemic effects of acacetin and 4, 5-o-dicaffeoylquinic acid methyl ester on serum uric acid levels in potassium oxonate-pretreated rats. Biol Pharm Bull, 2005;28;2231-2234.
  pubmed

• 31) Wilson D. W., Wilson H. C.:Studies in vitro of the digestion and absorption of purine ribonucleotides by the intestine. J Biol Chem, 1962;237;1643-1647.
  pubmed

• 32) Stow R. A., Bronk J. R.:Purine nucleoside transport and metabolism in isolated rat jejunum. J Physiol, 1993;468;311-324.
  pubmed

• 33) Parsons D. S., Shaw M. I.:Use of high performance liquid chromatography to study absorption and metabolism of purines by rat jejunum in vitro. Q J Exp Physiol, 1983;68;53-67.
  pubmed

• 34) Bronk J. R., Shaw M. I.:The transport of uric acid across mouse small intestine in vitro. J Physiol, 1986;378;229-39.
  pubmed

• 35) 小川順, 杉本聡, 清水昌ほか: プリンヌクレオシド代謝に影響を及ぼす乳酸菌の探索. 2004年度日本農芸化学会大会講演要旨集, 2004; 197.

• 36) 池永武, 久米村恵, 岡松洋ほか: 食事性高尿酸血症モデルラットの血中尿酸値に及ぼす乳酸菌の影響. 2004年度日本農芸化学会大会講演要旨集, 2004; 197.

• 37) 小川順, 妙中仁美, 杉本聡ほか: 高尿酸血症に有効な乳酸菌におけるプリン体代謝の解析. 2005年度日本農芸化学会大会講演要旨集, 2005; 244.

• 38) 寺尾純二, 山西倫太郎, 高村仁知: 食品機能学. 光生館, 2003.

• 39) Arai S., Osawa T., Ohigashi H. et al.:A main stay of functional food science in Japan-history, present status, and future outlook. Biosci Biotechnol Biochem, 2001;65;1-13

第3編 公衆栄養と疾病予防

P.178 掲載の参考文献

• 1) Sasaki S, Kesteloot H. Wine and non-wine alcohol:differential effect on all-cause and causespecific mortality. Nutr Metab Cardiovasc Dis 1994;4;177-82.

• 2) Connor SL, Ojeda LS, Sexton G, Weidner G, Connor WE.:Diets lower in folic acid and carotenoids are associated with the coronary disease epidemic in Central and Eastern Europe. J Am Diet Assoc 2004;104;1793-9.
  pubmed

• 3) Castelli WP.:Lipids, risk factors and ischaemic heart disease. Atherosclerosis 1996;124 Suppl;S1-9.

• 4) Di Castelnuovo A, Rotondo S, Iacoviello L, Donati MB, De Gaetano G.:Meta-analysis of wine and beer consumption in relation to vascular risk. Circulation 2002;105;2836-44.
  pubmed

• 5) Food, Nutrition and the Prevention of Cancer:a Global Perspective World Cancer Research Fund, American Institute for Cancer Research, 1997

• 6) Pawlak DB, Ebbeling CB, Ludwig DS.:Should obese patients be counselled to follow a lowglycaemic index diet? Yes. Obes Rev 2002;3;235-43.
  pubmed

• 7) Raben A.:Should obese patients be counselled to follow a low-glycaemic index diet? No. Obes Rev 2002;3;245-56.
  pubmed

• 8) Sasaki S, Kobayashi M, Tsugane S.:Development of substituted fatty acid food compositiontable for the use in nutritional epidemiologic studies for Japanese populations:its methodological backgrounds and the evaluation J Epidemiol 1999;9;190-207.
  pubmed

• 9) Tokudome Y, Imaeda N, Ikeda M, Kitagawa I, Fujiwara N, Tokudome S.:Foods contributing to absolute intake and variance in intake of fat, fatty acids and cholesterol in middle-aged Japanese. J Epidemiol 1999;9;78-90.
  pubmed

• 10) Kobayashi M, Sasaki S, Kawabata T, Hasegawa K, Tsugane S.:Validity of a self-administered food frequency questionnaire used in the 5-year follow-up survey of the JPHC Study Cohort I to assess fatty acid intake:comparison with dietary records and serum phospholipid level. J Epidemiol 2003;13(1 suppl);S64-S81.

• 11) Sasaki, et al.:Nutr Metab Cardiovasc Dis 1994;4;177-82

• 12) Connor et al.:J Am Diet Assoc 2004;104;1793-9

• 13) Di Castelnuovo et al.:Circulation 2002;105;2836-44

P.190 掲載の参考文献

• 1) 佐々木敏: わかりやすいEBNと栄養疫学, 同文書院, 2005

• 2) 須田立雄: 新骨の科学, 医歯薬出版, 2007

• 3) Favus MJ.:Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Sixth Edition. American Society for Bone and Mineral Research.

• 4) Raisz LG.:Pathogenesis of osteoporosis : concepts, conflicts, and prospects. J. Clin. Invest. 2005;115;3318-3325.
  pubmed

• 5) Asagiri M, Takayanagi H.:The molecular understanding of osteoclast differentiation. Bone 40;251-264

• 6) 骨粗鬆症の予防と治療ガイドライン作成委員会(編): 骨粗鬆症の予防と治療ガイドライン2006年版, ライフサイエンス出版, 2006

• 7) Lips P.:Vitamin D deficiency and secondary hyperparathyroidism in the elderly:consequences for bone loss and fractures and therapeutic implications. Endor Rev 2001;22;477-501

• 8) 第一出版編集部(編): 日本人の食事摂取基準 [2005年版], 第一出版, 2005

• 9) Jackson RD, LaCroix AZ, Gass M et al.:Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006;354;669-683

• 10) Tang BMP, Eslick GD, Nowson C et al.:Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older:a meta-analysis. Lancet 2007;370;657-666
  pubmed

• 11) Bischolff-Ferrari HA, Willett WC, Wong JB et al.:Fracture prevention with vitamin D supplementation. JAMA 2005;593;2257-2264

• 12) Luo G, Ducy P, McKee MD et al.:Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997;386;78-81

• 13) Ducy P, Desbois C, Boyce B et al.:Increased one formation in osteocalcin-deficient mice. Nature 1996;382;448-452,

• 14) Booth SL, Tucker KL, Chen H et al.:Dietary vitamin K intakes are associated with hip fracture but not with bone mineral density in elderly men and women. Am J Clin Nutr 2000;71;1201-1208
  pubmed

• 15) Vergnaud P, Garnero P, Meunier PJ et al.:Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture inelderly women:the EPIDOS Study. J Clin Endocrinol Metab 1997;82;719-724

• 16) Cockayne S, Adamson J, Lanham-New S et. al.:Vitamin K and the prevention of fractures : systematic review and meta-analysis of randomized controlled trials. Arch Intern Med. 2006;166;1256-61

• 17) McLean RR, Jacques PF, Selhub J et al.:Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med. 2004;350;2042-9

• 18) van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM et al.:Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med. 2004;350;2033-41

• 19) Stevenson M, Davis S, Lloyd-Jones M, et al.:The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women. Health Technol Assess. 2007;11(4);1-134,
  pubmed

• 20) Michaelsson K, Lithell H, Vessby B et al.:Serum retinol levels and the risk of fracture. N Engl J Med. 2003;348;287-94

P.198 掲載の参考文献

• 1) http://www.kenkounippon21.gr.jp/kenkounippon21/about/tsuuchibun/e-1.html
  pubmed

• 2) http://law.e-gov.go.jp/htmldata/H17/H17HO063.html

• 3) Yokoyama T, Yokoyama A et al.: Alcohol flushing, alcohol and aldehyde dehydrogenase genotypes, and risk for esophageal squoamous cells carcinoma in Japanese men. Cancer Epidemiol Biomarkers Prev 12;2003;1227-1233.

• 4) Toyasaki M, Yano M, Takii Y.:Detection of aldehyde dehydrogenase 2 gene fragment using nail clippings and saliva. J Biol Macromol;2002;2;91-94.

• 5) Singletary KW, Gapstur SM:Alcohol and breast cancer. Review of epidemiologic and experimental evidence and potential mechanisms. JAMA 286;2001;2143-2151.
  pubmed

• 6) Baan R, Staif K et al.:Carcinogenicity of alcoholic beverages. Lancet Oncol 2007;8;292-293

• 7) Higuchi S Matsusita S. et al.:Aldehyde dehydrogenase genotypes in Japanese alcoholics. Lancet;1994;741-742.

• 8) Suzuki Y, Fujisawa M et al.:Alcohol dehydrogenase 2 variant is associated with cerebral infraction and lacunae. Neurology;63;2004;1711-1713

• 9) 矢野めぐむ, 戸矢崎満美, 瀧井幸男: 女子大生におけるアルデヒド脱水素酵素遺伝子分布と体質判定法の検討; 日本食品化学学会会誌; 2005; 12; 145-151

• 10) Takii Y, Kuriyama N, Suzuki, Y.:Alkaline serine protease produced from citric acid by Bacillus alcalophilus subsp. haloduranse KP1239. Appl Microbiol Biotechnol;1990;34;57-62

• 11) Takii Y et al.:Cloning and expression in Bacillus brevis of alkaline serine protease gene from Bacillus alcalophilus sp. halodurans MIB 029. (submitted for publication)

• 12) Yoshida Y, Okuno T, Rakuman M, Takii Y.:The efficiency of DNA extraction from nail clipping is improved by using the proteases from Cucumis Melo. (submitted for publication)

• 13) Higuchi S:Significance of ethanol patch test. Nippon Rinsho (Japanese Journal of Clinical Medicine) ;1997;55 suppl. ;582-587

• 14) Yamada A et al.:Excerpta Medical Foundation International Congress Series. 1988;805;281-484

• 15) Mayer, J. Filstead, W. J.: The adolescent alcohol involvement scale. An instrument for measuring adolescents' use and misuse of alcohol. J Stud Alcohol;1979;40;291-300